Clinical outcomes of surgical management for primary gastrointestinal diffuse large B-cell lymphoma: At a single institution experienceClinical outcomes of surgical management for primary gastrointestinal diffuse large B-cell lymphoma: At a single institution experience
- Other Titles
- Clinical outcomes of surgical management for primary gastrointestinal diffuse large B-cell lymphoma: At a single institution experience
- Authors
- 장성우; 임대로; 국정걸; 김태형; 신응진
- Issue Date
- 2017
- Publisher
- 대한종양외과학회
- Keywords
- Lymphoma; Diffuse large B-cell lymphoma; Gastrointestinal tract; Surgery
- Citation
- 대한종양외과학회지, v.13, no.2, pp 75 - 82
- Pages
- 8
- Journal Title
- 대한종양외과학회지
- Volume
- 13
- Number
- 2
- Start Page
- 75
- End Page
- 82
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/8005
- ISSN
- 2288-4084
- Abstract
- Purpose: The study aimed to analyze peri/postoperative outcomes and long-term oncologic outcomes after surgical management for primary gastrointestinal diffuse large B-cell lymphoma (DLBL).
Methods: Between January 2001 and December 2013, 19 patients who underwent surgery for primary gastrointestinal DLBL were retrieved from a retrospective database.
Results: With a median follow up of 49.2 months, the most common tumor locations were the terminal ileum and cecum (n=14, 73.7%) and stomach (n=4, 21.1%). The most common clinical symptoms were abdominal pain (n=15, 78.9%) and intussusceptions (n=5, 26.3%).
None of the patients had B symptoms. Emergency surgery was undertaken in 36.8% (n=7) of the patients. Mean mass size was 8.4 cm; 4 patients (21.1%) had a bulky mass (>10 cm). The International Prognostic Index (IPI) scores were low (n=11, 57.9%), low-intermittent (n=7, 36.8%), and high-intermittent (n=1, 5.3%). Patients` staging was IE (n=9, 47.4%), IIE (n=8, 42.1%), and IVE (n=2, 10.5%) based on the Ann Arbor staging system, and I (n=2, 10.5%), II1 (n=5, 26.4%), IIE (n=10, 52.6%), and IV (n=2, 10.5%) based on the Lugano staging system.
B-lymphocyte antigen CD20 was positive in most patients (n=17, 89.5%) and Ki-67 was high (>70%) in 12 patients (63.2%). Two types of chemotherapy were administered: cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisolone (n=5, 26.3%), rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisolone (n=13, 68.4%). The 5-year disease-free survival rate was 94.4% and the 5-year overall survival rate was 89.5%.
Conclusion: Surgery for primary gastrointestinal DLBL is feasible and acceptable. Low staging of primary gastrointestinal DLBL has good prognosis.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of General Surgery > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/8005)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.